HER2在非小细胞肺癌临床分期中的预测价值

目的:人类表皮生长因子受体2(HER2)可能在肺癌的发生发展中，尤其在表皮生长因子受体1（EGFR）突变状态下，起着重要作用。我们探讨初治晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）血清HER2表达特征及临床意义。方法:本院肺癌研究所2012年9月到2013年6月血清标本共63例。用酶联免疫吸附测定法（ELISA）检测其外周血清中HER2表达水平。结果:HER2中位浓度为25.78ng/ml（10.29~488.28ng/ml），HER2浓度在不同的肿瘤大小、淋巴结转移及远处转移均有显著性差异（P=0.007、P=0.024、P=0.046）。与淋巴结转移、远处转移呈负相关（P=0.012，P=0.005）。HER2血清浓度定量与年龄、性别、组织学分类、病理学类型、治疗前CEA浓度、吸烟状态、EGFR突变状态均无统计学意义。结论:在外周血清中检测HER2是可行的，与临床特征存在相关性，HER2在肺癌的发展过程中发挥重要作用。

Clinical value of serum HER2 in the staging of non -small cell lung cancer

Objective:Human epidermal growth factor receptor 2 (HER2)may be in the development of lung cancer,especially in the EGFR mutation,it plays an important role.Treatment of advanced non -small cell lung canc-er(NSCLC)we study the serum HER2 expression and clinical significance.Methods:A total of 63 cases of serum samples were tested by enzyme -linked immunosorbent assay(ELISA)to detect the level of expression of serum HER2.Results:The median concentration of HER2 was 25.78ng/ml (10.29 ~488.28ng/ml),HER2 concentration in different tumor size ,lymph node metastasis and distant metastasis were significantly different(P =0.007,P =0.024,P =0.046).With lymph node metastasis,distant metastasis was negatively correlated(P =0.012,P =0.005). HER2 serum concentration was not related with age,gender,histological classification,pathology type,pretreatment CEA concentration,smoking status,EGFR mutations.Conclusion:HER2 in serum is feasible,and correlated with the clinical features.